MP73-04 PREDICTIVE VALUE OF SERUM CCL27 FOR RECURRENCE IN NON-MUSCLE-INVASIVE BLADDER CANCER FOLLOWING BCG IMMUNOTHERAPY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000959.04
Abstract: INTRODUCTION AND OBJECTIVE: Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is the gold-standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), while over 30% patients experience tumor recurrence following BCG therapy. We aimed to screen for reliable circulating… read more here.
Keywords: recurrence; ccl27; following bcg; serum ccl27 ... See more keywords
MP73-05 BCG-UNRESPONSIVE NMIBC, COMPARISON OF 2 ND -LINE INTRAVESICAL INSTILLATION THERAPY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000959.05
Abstract: INTRODUCTION AND OBJECTIVE: Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is the gold-standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), while over 30% patients experience tumor recurrence following BCG therapy. We aimed to screen for reliable circulating… read more here.
Keywords: therapy; following bcg; bcg therapy; bcg ... See more keywords